Ovopet® (eggshell membrane): a new ingredient to treat hip ... · Dry Petfood/placebo study in dogs with hip dysplasia 4. Snacks/placebo study in dogs with hip dysplasia. 1. Preliminary

Ovopet® (eggshell membrane): a new ingredient to treat hip

dysplasia in dogs

Erena Gil-Quintana

Quality and R&D Department

Eggnovo S.L. (www.eggnovo.com)

Ovopet® (eggshell membrane)

The ingredient is obtained through a patented method,removing the eggshell membrane from the calciumcarbonate

Eggshell membrane in powder

Calcium carbonate in powder

Eggshell membrane

Eggshell membrane is a natural protective barrier whichcontains many beneficial elements for health and wellness.

38%

10%

4%2%2%1%1%

42%

Collagen 38%

Sulfur bearing amino acids 10%

Hyaluronic acid 4%

Glucosamine 2%

Chondroitin sulfate 2%

Keratin 1%

Lysozyme 1%

Other elements (ovocalixin, ovocleidin, elastin, desmosine...)

Eggshell membrane composition

• Mostly from type I which is present in the vascularsystem, skin, tendons, ligaments and bones.

• Collagen type I is more absorbable and digestiblethan collagen type II.

• It activates the synthesis of hyaluronic acid andendogen collagen.

Collagen


• The HA present in ovopet® is of high molecularweight (over 650KDa), the one shown effective forjoint health.

• It is important for the joints lubrication.

• It increases viscosity and reduces friction betweenarticular surfaces.

Hyaluronic acid (HA)


• It plays a main role in the cartilage’s integritymaintenance.

• It activates the synthesis of collagen andchondroitin sulphate.

• It reduces the progression of arthritis andosteoarthritis symptoms.

Glucosamine


• It is an effective protector of the cartilage, synovialmembrane and sub-chondral bone.

• It decreases some factors which produce theinflammatory processes.

Chondroitin sulphate


• They are critical substrates for protein synthesis and tosynthetize the chondroitin matrix of cartilage andglucosaminoglycans synthesis.

Sulfur bearing amino acids

• The enzyme has important antibacterial effects and itmodulates the immune system.

Lysozime

Eggshell membrane

• The eggshell membrane is moreeffective due to the synergy ofits compounds.

• There are several studies whichprove that the components’synergy it’s among 5 and 6times more effective than theeffects of the componentsthemselves.

Benefits

• Eggshell membrane (Ovopet®) shows 4 mainbenefits:

• Anti-inflammatory

• Analgesic

• Joint regenerator

• Tendon protection

Benefits

• It is specially effective in:

• Helping in joint function

• Strengthening joints

• Reducing joint pain

• Treating osteoarthritis and arthritis

• Preventing joint lesions

• Treating hip dysplasia

• Osteoarthritis is a highly prevalent condition indogs

Osteoarthritis

Performed studies

1. Preliminary study: capsules

2. CBPI based study: snacks

3. Dry Petfood/placebo study in dogs with hip dysplasia

4. Snacks/placebo study in dogs with hip dysplasia

1. Preliminary study: capsules

• 9 patients (7 canine+2 feline)

• 50 days of treatment

• 15 mg Ovopet®/Kg*day

• Veterinary opinion

In the opinion of theveterinary 67 % of the

patients improved fromtheir joint problems

2. Study: snacks

To assess the effectiveness of a chondroprotectivesnack made with Ovopet® (eggshell membrane) inosteoarthritic dogs.

Study Aim

2. Study: snacks

• 16 patients

• 60 days of treatment

• 12 mg Ovopet®Kg -1 dog day -1

• Monitoring:

Study Design

Day 0 Day 20 Day 40 Day 60

2. Study: snacks

• Veterinary monitoring

• Based on a validated test for chronic pain and

treatment for dogs with osteoarthritis (CBPI)

• Owners satisfaction questionnaire

Study Design

2. Study: snacks

The CBPI is divided in three categories:

• Description of pain

• Description of function

• Overall impression

The CBPI allows owners to rate the severity of their dogs pain

and the degree to which that pain interferes with function1.

CBPI rating scale

0No pain/ Doesnot interfere

10Extreme pain/

Completely Interferes

Study Design

1 Brown DC (2013) The Canine Brief Pain Inventory User Guide.

2. Study: snacks Results

100

90

76

70


Description of Pain (%)

30% of decrease in pain after 60 days of

treatment

30%24%10%

**


100

80

73

66

Day 0

Day 20

Day 40

Day 60

Description of Function (%)

20%34% of improvementin function after 60 days of treatment

34%

27%

CBPI rating scale

0No pain/ Does not

interfere

10Extreme pain/

Completely Interferes


36%

64%73%

82%

64%

36%27%

18%


% P

atie

nts

Overall impression (quality of life)

Good-Very Good Poor-Fair

Good-Very GoodPoor-Fair

Quality of life

46% of improvement in the overall impression

after 60 days of treatment

2. Study: snacks

Conclusions

• Visible results from the beginning of treatment

• Significant pain decrease

• Function increase (improvement in the ability to climb, to rise, to walk and to run)

• Significant improvement in the dog’s overallimpression

3. Dry pet food/placebo study in dogs with hip dysplasia

To assess the effectiveness of Ovopet® (eggshellmembrane) in the treatment of hip dysplasia in dogs.

Study Aim

3. Dry pet food/placebo study

• Difficulty standing up

• Difficulty using stairs

• Pain when jumping

• Loss of muscle mass in the affected leg

Symptoms of Dysplasia

3. Dry pet food/placebo

15 mg Kg-1 dog day-1

40 dogs

Study Design20 dogs

Placebo

Veterinary monitoring


Double blind

• Muscular atrophy

• Hip functional questionnaire

Conducted measurements


Muscular perimeter (cm) Extension (degrees)

• Hip mobility range

Flexion (degrees)

• Evaluation questionnaire with the owner

• Blood samples for inflammatory markers

• Side effects questionnaire



Results3. Dry pet food/placebo

Males41%

Females59%

Sex

10%

59%

19%12%

Osteoartritis grade (Kellgren-Lawrence grading scale)

Age 7.8 ± 1.0 years

Weight 31.3 ± 1.6 Kg

German shepherd

33%

Labrador16%

Golden13%

Cocker11%

Other breeds

27%

Breed

Grade 1 Grade 2 Grade 3 Grade 4


100

101

102

105

100 100101

99


Rig

ht

low

er li

mb

Muscular atrophy(% of improvement)

Ovopet® Placebo

100

102

103

105

100

102102

101


Left

low

er li

mb

Muscular atrophy(% of improvement)

Ovopet® Placebo

6% of improvement in themuscular perimeter at day 40

4% of improvement in themuscular perimeter at day 40

6% 4%


Extension grade 2,6 %

Extension (degrees)

% Improvement after 40 days of treatment

Hip mobility range

Hip functional questionnaire

The hip functional scale is an adaptation of a questionnaire that the R&Ddepartment of the dry petfood manufacturer employs for researching.

Two sections:• Functional limitation

• Joint mobility


Black asterisks (*) indicatesignificant differences(Student’s t-test, P ≤ 0.05)between ovopet® andplacebo treatments; yellowasterisks (*) indicatesignificant differences inovopet® during time.


Black asterisks (*) indicate significant differences (Student’s t-test, P ≤ 0.05) between ovopet® andplacebo treatments; yellow asterisks (*) indicate significant differences in ovopet® during time.

*

Results3. Dry pet food/placeboEvaluation questionnaire with the owner


Evaluation questionnaire with the owner


Visual scale The pain you think suffers your dog



5.2

15.4

0

5

10

15

NO TNF-a

% o

f im

pro

vem

ent

Day 40

Blood markers

Inflammatory blood markers


Possible side effects related to the treatment

No significant side effects

Not related to the ingredient

• Safe ingredient for dogs

• Reduces the muscular atrophy

• Improves the functional limitation by decreasing the lameness and the resistance to walk, to run and to climb up stairs

Conclusions


• Enhances the general activity of the dog

• Declines the levels of inflammatory blood markers

(Nitric oxide and TNF-α)

• Suitable for the inclusion into dry petfood

Conclusions


4. Snacks/placebo study in dogs with hip dysplasia

To assess the effectiveness of Ovopet® (eggshellmembrane) in the treatment of hip dysplasia in dogs.

Study Aim

4. Snack/placebo

15 mg Kg-1 dog day-1

30 dogs

Study Design

10 dogs

Placebo

Veterinary monitoring


Double blind

Day 40

• Muscular atrophy

• Hip functional questionnaire


4. Snack/placebo

Muscular perimeter (cm) Extension (degrees)

• Hip mobility range

Flexion (degrees)

• Evaluation questionnaire with the owner

• Blood samples for inflammatory markers

• Hip sonography

• Side effects questionnaire


4. Snack/placebo

Results4. Snack/placebo

Age 8 ± 0,56 years

Weight 34 ± 1,05 Kg

males37%

females63%

SEX

20%23%

25%

33%

0%

10%

20%

30%

40%

Grade 1 Grade 2 Grade 3 Grade 4

Osteoarthritis degree(Kellgren-Lawrence grading scale)

German shepherd

40%

Labrador15%

Golden15%

Gos d'atura

10%

Other breeds

20%

Breed

Results4. Snacks/placebo

9% of improvement in the muscular perimeter at day 40 in the dogs treated

with Ovopet®

7% of improvement in the muscular perimeter at day 40 in the dogs treated

with Ovopet®

Results4. Snack/placebo

Flexion grade 10,3 %

% Improvement after 40 days of treatment

Hip mobility range

Hip functional questionnaire

The hip functional scale is an adaptation of a questionnaire that the R&Ddepartment of the dry petfood manufacturer employs for researching.

Two sections:• Functional limitation

• Joint mobility

Flexion (degrees)


Black asterisks (*) indicate significant differences (Student’s t-test, P ≤ 0.05) between ovopet® and placebotreatments; yellow asterisks (*) indicate significant differences in ovopet® during time.

(1.13)

5.32 6.07

9.83

-5

0

5

10

15


% o

f im

pro

vem

en

t

FUNCTIONAL LIMITATION


Joint mobility


Black asterisks (*) indicate significant differences (Student’s t-test, P ≤ 0.05) between ovopet® and placebotreatments; yellow asterisks (*) indicate significant differences in ovopet® during time.



Visual scale

• The pain you think suffers your dog


Inflammatory blood markers

27

5

0

10

20

30

NO TNF-a

% o

f im

pro

vem

en

t

Day 40

Blood markers

Results4. Snacks/placeboHip Sonography

• Reduces the muscular atrophy

• Improves the functional limitation

• Decreases the pain

• Enhances the general activity of the dog

Conclusions

4. Snack/placebo

• Declines the levels of inflammatory blood markers

(Nitric oxide and TNF-α)

• Decreases the synovitis (40% reduction of

inflammation)

• Suitable for the inclusion into snacks

Conclusions

4. Snack/placebo

General conclusions

• It shows short-term benefits (the first 10 days)

• It is a safe ingredient

• It can be introduced in diverse formats:capsules, tablets, snacks, dry petfood…

Eggshell membrane:

General conclusions

• The negative effects of osteoarthritis asreduced mobility and stiffness

• Inflammation

• The pain in the affected pets

Eggshell membrane alleviates:

General conclusions

• A preventive measure for:

Pets and sensitive breeds prone to joint problems

• Offers strong evidence to support a jointmobility claim

Agility; Pain reduction; Prevention of jointproblems

Eggshell membrane can be recommended as:

Thank you for your attention

Eggshell membranewww.eggnovo.com

[email protected]

[email protected]

Documents

Ovopet® (eggshell membrane): a new ingredient to treat hip ... · Dry Petfood/placebo study in dogs with hip dysplasia 4. Snacks/placebo study in dogs with hip dysplasia. 1. Preliminary